AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PGNY

Progyny: Q3 Earnings Snapshot

Progyny Inc. (PGNY) reported Q3 earnings of $26.3M, or 32 cents per share, with adjusted EPS of 52 cents. Revenue was $341.3M. The company forecasts Q4 EPS of 53-58 cents and revenue of $344.7M-$364.7M. Full-year EPS is expected to be $2.09-$2.13 on revenue of $1.37B-$1.39B.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Progyny: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PGNYBullishHigh
01

Why it matters

The Q3 earnings beat and forward guidance give traders fresh data to position ahead of the next earnings cycle.

02

Market read

First‑report earnings release with new guidance for a mid‑cap health‑benefits firm.

03

What to watch

Potential headwinds from employer cost‑containment or changes in benefits adoption rates.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Progyny is a provider of fertility and family‑building benefits to employers and insurers.

Company-level read

Ticker impact

$PGNYBullishHigh confidence
Context

Progyny reported Q3 earnings of $26.3M, net income of 32¢ per share and provided Q4 revenue and EPS guidance.

Expected impact

likely modest upside as the beat may lift sentiment

Evidence & confidence

Fresh earnings and guidance are primary information; investors can react immediately.

Market effects

Sector

Provides a data point for the fertility‑benefits sector and may influence peer valuations.

Regional

Limited to U.S. markets where PGNY trades.

Global

Low global impact beyond the niche health‑benefits space.

Counterpoint

What could challenge this read

If guidance is seen as modest, the stock could face pressure despite the earnings beat.

Key entities

  • company
    Progyny Inc.

    US‑listed provider of fertility benefits.

Read at source← All news

StoryProgyny reports third-quarter revenue growth and raises full-year guidance

Also covered by

3 outlets

Related articles

$PGNYMed

Progyny (PGNY) Q3 2026 Earnings Call Transcript

Progyny (PGNY) reported record revenue and profitability for Q3 2026, with strong cash flow used for growth and share repurchases. The company added 1.3M new covered lives and 85 new clients, raising full-year guidance. Management highlighted strong demand for family building and women's health benefits, diverse client base, and market differentiation. Retention was near 100%, with 20% of clients expanding services. Progyny Select, a new offering, is expected to contribute to long-term growth.

finance.yahoo.com
$PGNYMedAI 8/10

Progyny 3Q 2026: Revenue $341.25M, EPS $0.32 — 10-Q Summary

Progyny reported 3Q 2026 revenue of $341.25M, up 8.9% YoY, and net income of $26.25M, up 89.4% YoY. Growth was driven by increased client and covered-life counts, improving gross margin to 24.5%. Fertility benefits and Progyny Rx revenue rose 11% and 6%, respectively. The company served 607 clients and 7.155M members as of September 30, 2026.

tradingview.com
$PGNYHigh

Progyny Q3 Earnings Call Highlights

Progyny (PGNY) reported Q3 earnings, highlighting a 130 basis point gross margin expansion and $56M in operating cash flow. CEO Anevski noted high client attach rates for Progyny Rx and expects 3M lives to access expanded products by 2027. The company repurchased 3M shares for $83M and plans to taper investments in 2027.

finance.yahoo.com